The effects of helium-hyperoxia on 6-min walking distance in COPD: A randomized, controlled trial

Chest

Volumn 131, Issue 6, 2007, Pages 1659-1665

  Marciniuk, Darcy D ^a,c   Butcher, Scott J ^b   Reid, John K ^a   MacDonald, G Fred ^b   Eves, Neil D ^b   Clemens, Ron ^a   Jones, Richard L ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

6 min walk test; COPD; Exercise; Helium hyperoxia

Indexed keywords

HELIUM; OXYGEN;

ADULT; AGED; AMBIENT AIR; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DYSPNEA; EXERCISE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HELIUM HYPEROXIA; HUMAN; HYPEROXIA; LEG FATIGUE; LUNG FUNCTION; MALE; MASK; OXYGEN BREATHING; OXYGEN MASK; OXYGEN SATURATION; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING; WALKING DISTANCE;

EID: 34250843216     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2514     Document Type: Article

References (27)

1. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
2. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. Can Respir J 2004; 11(suppl): 7B-59B
3. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:892-898
4. Cukier A, Ferreira CA, Stelmach R, et al. The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. Respir Med 2007; 101:746-753
5. Eves ND, Petersen SR, Haykowsky MJ, et al. Helium-hyperoxia, exercise, and respiratoiy mechanics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:763-771
6. Lande EA, Duffy NC, Baveystock C, et al. The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. Am J Respir Crit Care Med 2006; 173:865-870
7. Palange P, Valli G, Onorati R, et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 2004; 97:1637-1642
8. Barst RJ, Langlebern D, Frost A, et al. Sitaxasentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169:441-447
9. Liesker JJW, Wijkstra PJ, ten Hacken NHT, et al. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121:597-608
10. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41:2119-2125
11. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117
12. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664
13. Goldman HJ, Becklake ME. Respiratory function tests: normal values at mean altitudes and the prediction of normal results. Am Rev Tuberc Pulm Dis 1959; 79:457-467
14. Borg GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
15. Weisman IM, Beck K, Casaburi R, et al. American Thoracic Society/American College of Chest Physicians joint statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277
16. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390-1413
17. Bradley JM, O'Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (database online). Issue 4, 2005
18. Maltais F, Marciniuk DD, Hernandez P, et al. Improvements in symptom-limited exercise performance over eight hours with once-daily tiotropium in patients with COPD. Chest 2005; 128:1168-1178
19. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86-94
20. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127:809-817
21. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax 2006; 61:559-567
22. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012
23. Martinez FJ, Foster G, Curtis J L, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006; 173:1326-1334
24. Thorstensson A, Roberthson H. Adaptations to changing speed in human locomotion: speed of transition between walking and running. Acta Physiol Scand 1987; 131:211-214
25. Neptune RR, Sasaki K. Ankle plantar flexor force production is an important determinant of the preferred walk-to-run transition speed. J Exp Biol 2005; 208:799-808
26. Redelmeier DA, Bayoumi AM, Goldstein R, et al. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155:1278-1282
27. Ponlain M, Durand F, Palomba B, et al. 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest 2003; 123:1401-1407